Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019
Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019
SUMMARY
Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-?1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.
Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 9 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Respiratory, Cardiovascular, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Central Nervous System, Genetic Disorders, Hematological Disorders and Metabolic Disorders which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Breast Cancer, Kidney Fibrosis, Osteoarthritis, Solid Tumor, Squamous Cell Carcinoma, Anemia, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Disorders, Cholangitis, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hepatocellular Carcinoma, Hyperalgesia, Hypertrophic Scars, Inflammation, Liver Fibrosis, Lung Adenocarcinoma, Melanoma, Metastatic Breast Cancer, Myelofibrosis, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Nonmelanomatous Skin Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pancreatic Cancer, Pancreatitis Pain, Peripheral Artery Occlusive Disease (PAOD), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Primary Sclerosing Cholangitis, Proliferative Vitreoretinopathy (PVR), Pulmonary Hypertension, Scar and Systemic Sclerosis (Scleroderma).
The latest report Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-?1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.
Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 9 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Respiratory, Cardiovascular, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Central Nervous System, Genetic Disorders, Hematological Disorders and Metabolic Disorders which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Breast Cancer, Kidney Fibrosis, Osteoarthritis, Solid Tumor, Squamous Cell Carcinoma, Anemia, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Disorders, Cholangitis, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hepatocellular Carcinoma, Hyperalgesia, Hypertrophic Scars, Inflammation, Liver Fibrosis, Lung Adenocarcinoma, Melanoma, Metastatic Breast Cancer, Myelofibrosis, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Nonmelanomatous Skin Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pancreatic Cancer, Pancreatitis Pain, Peripheral Artery Occlusive Disease (PAOD), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Primary Sclerosing Cholangitis, Proliferative Vitreoretinopathy (PVR), Pulmonary Hypertension, Scar and Systemic Sclerosis (Scleroderma).
The latest report Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
- The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Transforming Growth Factor Beta 1 (TGFB1) - Overview
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
AlfaSigma SpA
Avacta Life Sciences Ltd
Bonac Corp
Ensol Biosciences Inc
Forbius
Genzyme Corp
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Phio Pharmaceuticals Corp
Scholar Rock Inc
Sirnaomics Inc
Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides to Inhibit TGFB1 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVID-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-1021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Engedi-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluorofenidone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Latent TGFB1 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TGF Beta1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TGFB1 for Oncology, Gastrointestinal and Genito Urinary System and Sex Hormones Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 1 to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGF-Beta-1 for Chronic Pancreatitis Pain and Hyperalgesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit TGF Beta 1 for Squamous Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TGFB1 for Camurati-Engelmann Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TGFB1 for Idiopathic Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRK-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulodexide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products
Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2019: Forbius completes phase 1 oncology dose-escalation with AVID200, first-in-class TGF-beta 1 & 3 inhibitor: Well tolerated, target inhibition demonstrated at all dose levels, data reported at SITC
Nov 06, 2019: Sirnaomics to Present Overview of Company's RNAi Technology Platform at Upcoming Conferences
Nov 05, 2019: Forbius to report phase 1a oncology clinical data with AVID200, first-in-class TGF-beta 1 & 3 inhibitor, in late-breaking poster presentation
Oct 31, 2019: Sirnaomics to present preclinical STP705 data suggesting reduction in Liver Fibrosis at AASLD Liver Meeting
Oct 14, 2019: Forbius completes enrollment into phase 1a solid tumor trial of AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor; Closes Series C Financing
Sep 28, 2019: ESMO 2019: Forbius demonstrates target engagement in Phase 1 immuno-oncology clinical trial with AVID200, first-in-class TGF-beta 1 & 3 Inhibitor
Sep 23, 2019: Forbius announces AVID200, a first-in-class TGF-beta 1 & 3 selective inhibitor, to be featured at ESMO and CICON 2019
May 16, 2019: Sirnaomics publishes data for lead candidate STP705 in Cancer Model as 2019 American Society of Clinical Oncology Annual Meeting Online Abstract
Apr 29, 2019: Forbius’ AVID200, a Novel TGF-beta 1 & 3 inhibitor, cleared by Health Canada to commence phase 1 clinical trial in Solid Tumors
Apr 24, 2019: Forbius: First patient dosed in a phase 1b Myelofibrosis trial of AVID200, a novel TGF-beta 1 & 3 inhibitor
Apr 08, 2019: Sirnaomics to present at World Orphan Drug Congress 2019
Apr 02, 2019: Scholar Rock presents additional preclinical data demonstrating a highly specific inhibitor of TGF?1 activation can render resistant solid tumors vulnerable to PD1 blockade and drive tumor regression with combination therapy
Mar 12, 2019: Scholar Rock to develop cancer immunotherapy product candidate, SRK-181, a selective inhibitor of TGF?1 activation, to overcome checkpoint inhibitor resistance
Mar 04, 2019: Forbius announces the first patient dosed in a phase 1b diffuse cutaneous systemic sclerosis trial of AVID200, a novel TGF-beta 1 & 3 inhibitor
Mar 04, 2019: Forbius announces the first patient dosed in a phase 1b diffuse scleroderma trial of AVID200, a novel TGF-beta 1 & 3 inhibitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Transforming Growth Factor Beta 1 (TGFB1) - Overview
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
AlfaSigma SpA
Avacta Life Sciences Ltd
Bonac Corp
Ensol Biosciences Inc
Forbius
Genzyme Corp
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Phio Pharmaceuticals Corp
Scholar Rock Inc
Sirnaomics Inc
Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides to Inhibit TGFB1 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVID-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-1021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Engedi-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluorofenidone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-1106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Latent TGFB1 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TGF Beta1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TGFB1 for Oncology, Gastrointestinal and Genito Urinary System and Sex Hormones Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 1 to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGF-Beta-1 for Chronic Pancreatitis Pain and Hyperalgesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TGFB1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit TGF Beta 1 for Squamous Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TGFB1 for Camurati-Engelmann Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TGFB1 for Idiopathic Pulmonary Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRK-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulodexide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products
Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones
Featured News & Press Releases
Nov 08, 2019: Forbius completes phase 1 oncology dose-escalation with AVID200, first-in-class TGF-beta 1 & 3 inhibitor: Well tolerated, target inhibition demonstrated at all dose levels, data reported at SITC
Nov 06, 2019: Sirnaomics to Present Overview of Company's RNAi Technology Platform at Upcoming Conferences
Nov 05, 2019: Forbius to report phase 1a oncology clinical data with AVID200, first-in-class TGF-beta 1 & 3 inhibitor, in late-breaking poster presentation
Oct 31, 2019: Sirnaomics to present preclinical STP705 data suggesting reduction in Liver Fibrosis at AASLD Liver Meeting
Oct 14, 2019: Forbius completes enrollment into phase 1a solid tumor trial of AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor; Closes Series C Financing
Sep 28, 2019: ESMO 2019: Forbius demonstrates target engagement in Phase 1 immuno-oncology clinical trial with AVID200, first-in-class TGF-beta 1 & 3 Inhibitor
Sep 23, 2019: Forbius announces AVID200, a first-in-class TGF-beta 1 & 3 selective inhibitor, to be featured at ESMO and CICON 2019
May 16, 2019: Sirnaomics publishes data for lead candidate STP705 in Cancer Model as 2019 American Society of Clinical Oncology Annual Meeting Online Abstract
Apr 29, 2019: Forbius’ AVID200, a Novel TGF-beta 1 & 3 inhibitor, cleared by Health Canada to commence phase 1 clinical trial in Solid Tumors
Apr 24, 2019: Forbius: First patient dosed in a phase 1b Myelofibrosis trial of AVID200, a novel TGF-beta 1 & 3 inhibitor
Apr 08, 2019: Sirnaomics to present at World Orphan Drug Congress 2019
Apr 02, 2019: Scholar Rock presents additional preclinical data demonstrating a highly specific inhibitor of TGF?1 activation can render resistant solid tumors vulnerable to PD1 blockade and drive tumor regression with combination therapy
Mar 12, 2019: Scholar Rock to develop cancer immunotherapy product candidate, SRK-181, a selective inhibitor of TGF?1 activation, to overcome checkpoint inhibitor resistance
Mar 04, 2019: Forbius announces the first patient dosed in a phase 1b diffuse cutaneous systemic sclerosis trial of AVID200, a novel TGF-beta 1 & 3 inhibitor
Mar 04, 2019: Forbius announces the first patient dosed in a phase 1b diffuse scleroderma trial of AVID200, a novel TGF-beta 1 & 3 inhibitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AlfaSigma SpA, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by Bonac Corp, H2 2019
Pipeline by Ensol Biosciences Inc, H2 2019
Pipeline by Forbius, H2 2019
Pipeline by Genzyme Corp, H2 2019
Pipeline by Huabo Biopharm Co Ltd, H2 2019
Pipeline by Isarna Therapeutics GmbH, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Phio Pharmaceuticals Corp, H2 2019
Pipeline by Scholar Rock Inc, H2 2019
Pipeline by Sirnaomics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AlfaSigma SpA, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by Bonac Corp, H2 2019
Pipeline by Ensol Biosciences Inc, H2 2019
Pipeline by Forbius, H2 2019
Pipeline by Genzyme Corp, H2 2019
Pipeline by Huabo Biopharm Co Ltd, H2 2019
Pipeline by Isarna Therapeutics GmbH, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Phio Pharmaceuticals Corp, H2 2019
Pipeline by Scholar Rock Inc, H2 2019
Pipeline by Sirnaomics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
AlfaSigma SpA
Avacta Life Sciences Ltd
Bonac Corp
Ensol Biosciences Inc
Forbius
Genzyme Corp
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Phio Pharmaceuticals Corp
Scholar Rock Inc
Sirnaomics Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
AlfaSigma SpA
Avacta Life Sciences Ltd
Bonac Corp
Ensol Biosciences Inc
Forbius
Genzyme Corp
Huabo Biopharm Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Novartis AG
Phio Pharmaceuticals Corp
Scholar Rock Inc
Sirnaomics Inc
